Previous studies have identified TF-related gene signatures and risk score models in colorectal cancer, glioblastoma, breast cancer, endometrial cancer, ovarian cancer and gastric cancer, suggesting that TF-based signatures can predict prognosis and therapeutic efficacy for cancer patients [7–14]. This evidence concerns the gene TF and ovarian carcinoma.